SCHEMBL6403067

SCHEMBL6403067

CC(C)[C@@H](CS(=O)(=O)Cc1ccc2sccc2c1)N(O)C=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.38
MMP2 P08253 2/20 0.36
MMP13 P45452 2/20 0.36
CA2 P00918 5/20 0.33
CA12 O43570 4/20 0.33
OPRM1 P35372 1/20 0.33
OPRK1 P41145 1/20 0.33
PER2 O15055 1/20 0.32
CRY1 Q16526 1/20 0.32
CRY2 Q49AN0 1/20 0.32
TPSAB1 Q15661 1/20 0.32
PDE10A Q9Y233 1/20 0.32
MMP1 P03956 1/20 0.32
MMP3 P08254 1/20 0.32
MMP7 P09237 1/20 0.32
MMP10 P09238 1/20 0.32
MMP9 P14780 1/20 0.32
MMP8 P22894 1/20 0.32
MMP12 P39900 1/20 0.32
MMP14 P50281 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6608461 1.00 CYP2A6 (0.38) CYP2A6MMP2MMP13CA2CA12
SCHEMBL6607289 0.92 MMP2 (0.36) CYP2A6MMP2MMP13TPSAB1MMP1
SCHEMBL6608267 0.89 CYP2A6 (0.40) CYP2A6MMP2MMP13CA2CA12
SCHEMBL6608264 0.89 CYP2A6 (0.40) CYP2A6MMP2MMP13CA2CA12
SCHEMBL6399305 0.85 CYP2A6 (0.36) CYP2A6MMP2MMP13CA2CA12
SCHEMBL6405755 0.82 HPGD (0.38) CYP2A6MMP2MMP13CA2CA12
SCHEMBL6405750 0.82 HPGD (0.38) CYP2A6MMP2MMP13CA2CA12
SCHEMBL6399504 0.82 CYP2A6 (0.36) CYP2A6MMP2MMP13CA2CA12
SCHEMBL6608049 0.82 CYP2A6 (0.36) CYP2A6MMP2MMP13CA2CA12
SCHEMBL6399565 0.81 CYP2A6 (0.35) CYP2A6MMP2MMP13CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides SMITHKLINE BEECHAM PLC 2005-12-29 US claimed
EP-1289980-B1 BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES SMITHKLINE BEECHAM PLC (GB) 2004-11-17 EP claimed
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-05 US claimed
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides SMITHKLINE BEECHAM PLC 2005-12-29 US disclosed
EP-1289980-B1 BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES SMITHKLINE BEECHAM PLC (GB) 2004-11-17 EP disclosed
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides CD22, CD2, NEU3 CYP2A6 486/4885MMP2 2931/4885MMP13 469/4885
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides CD22, CD2, NEU3 CYP2A6 459/4885MMP2 2846/4885MMP13 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.